Vienna, Austria, 06 May 2025 — MicroPort EverPace and MicroPort® CRM jointly participated in the European Heart Rhythm Association Congress (EHRA 2025) to present its comprehensive portfolio in Cardiac Rhythm Management (CRM) and Electrophysiology (EP). During the three-day congress, the MicroPort® booth drew significant interest from healthcare professionals, with interactive workstations offering hands-on experiences across the entire spectrum of CRM and EP solutions.
MicroPort EverPace presented its full range of EP interventional diagnosis and treatment solutions, centered on four major technology pillars: cryoablation (cryo), radiofrequency ablation (RFA), pulsed field ablation (PFA), and magnetic navigation.
Throughout the congress, EverPace experts attracted a wide audience while sharing the latest R&D breakthroughs during four keynote speeches at the booth around the “Cryo, RF, PFA, and Magnetic Navigation” topics. The presentations concentrated on key technical features, and clinical research data for
In the hands-on experience zone, physicians explored advanced tools such as the EasyLoop™ 3D Circular Mapping Catheter and EasyStars™ 3D High Density Mapping Catheter, and the FireMagic™ TrueForce™ Ablation Catheter.
Meanwhile, MicroPort® CRM presented its comprehensive solutions spanning disease diagnosis, treatment, and post-operative patient monitoring. The Leads Portfolio station stood out with continuous interactions on Left Bundle Branch Area Pacing (LBBAP), generating high interest and extremely positive feedback from physicians about its potential impact on patient care.
The myPatch®sl technology drew continued attention, with numerous requests for more information about its applications. Meanwhile, the SyneScope® Easy Cloud reinforced the importance of seamless diagnostic solutions in today’s evolving healthcare landscape, while the newly introduced SmartView Connect™ App Mobile exemplified the ongoing evolution of remote patient monitoring.
Four interactive workstations — Ablation Experience, Physiological Pacing / Leads Portfolio, Diagnostic Experience, and Implant and Follow-up Experience — remained packed throughout the event, attracting more participants than expected. Selected delegates also had the exclusive opportunity to preview and test next-generation solutions currently under development or in clinical evaluation, including upcoming LBBAP solution.
EHRA 2025 also provided an opportunity to take a moment to celebrate the 30th anniversary of the world’s first dual-chamber ICD — the DEFENDER™ 9001 — a pioneering innovation by MicroPort® CRM, while expressing our gratitude to customers for their continued support throughout the years.
Through their strong presence at EHRA 2025, MicroPort® EP and MicroPort® CRM reaffirmed their commitment to continuous innovation, responding to the evolving needs of clinicians and patients worldwide with advanced, integrated cardiac solutions.
About MicroPort EverPace
Founded in 2010, MicroPort EverPace (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and commercializing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 1100 hospitals over more than 30 countries. MicroPort EverPace strives to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at: www.everpace.com/en
About MicroPort CRM
MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France. Through our long-standing expertise in CRM, MicroPort® CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure. Our state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic.
More information is available at: www.microport.com